The tumor suppressive microRNA miR-218 targets the mTOR component rictor and inhibits AKT phosphorylation in oral cancer

Cancer Research

Volumn 71, Issue 17, 2011, Pages 5765-5778

  Uesugi, Atsushi ^a   Kozaki, Ken Ichi ^a   Tsuruta, Tomohiko ^a   Furuta, Mayuko ^a   Morita, Kei Ichi ^a   Imoto, Issei ^a   Omura, Ken ^a   Inazawa, Johji ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 2; CHECKPOINT KINASE 1; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 218; MICRORNA 585; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN RICTOR; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CHROMOSOME 4P; CHROMOSOME 5P; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EGFR COAMPLIFIED AND OVEREXPRESSED PROTEIN GENE; EGFR GENE; GENE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC SCREENING; HUMAN; HUMAN CELL; I KAPPA B KINASE GENE; INTRON; LIM AND SH3 PROTEIN 1 GENE; MOUTH CANCER; ORAL SQUAMOUS CELL CARCINOMA; PAXILLIN GENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; PROTO ONCOGENE JUNB; PTEN GENE; RNA GENE; ROBO1 GENE; SQUAMOUS CELL CARCINOMA; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; MOUTH NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

EID: 80052218238     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0368     Document Type: Article

References (43)

1. Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5. (Pubitemid 39265675)
2. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005;15:563-8. (Pubitemid 41262414)
3. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8. (Pubitemid 40839735)
4. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
5. Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 2007;28:2-12. (Pubitemid 44942621)
6. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54. (Pubitemid 37448928)
7. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr Res 2007;61:24R-9R. (Pubitemid 46653064)
8. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008;68:2094-105. (Pubitemid 351521781)
9. Furuta M, Kozaki K, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2009;31:766-76.
10. Iorio MV, Piovan C, Croce CM. Interplay between microRNAs and the epigenetic machinery: An intricate network. Biochim Biophys Acta 2010;1799:10-2.
11. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
12. Nomura K, Sobue T, Nakatani H, Maehara M, Kiryu Y, Tsukuma H, et al. The Editorial Board of Cancer Statistics in Japan. Number of deaths and proportional mortality rates from malignant neoplasms by site in Japan (2003). Cancer Statistics in Japan 2005;36-9. Available from:http://www.ncc.go.jp/en/ statistics/index.html.
13. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol 2000;36:256-63. (Pubitemid 30227706)
14. Ha PK, Califano JA. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 2006;7:77-82. (Pubitemid 43025396)
15. Nakano H, Miyazawa T, Kinoshita K, Yamada Y, Yoshida T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer 2010;127:1072-80.
16. Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, Pinner S, et al. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell 2010;40:841-9.
17. Suzuki E, Imoto I, Pimkhaokham A, Nakagawa T, Kamata N, Kozaki K, et al. PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation. Oncogene 2007;26:7921-32. (Pubitemid 350261784)
18. Available from miRBase database (Release 17 April 2011): http://www.mirbase.org/index.shtml.
19. Available from UCSC Genome Browser on Human February 2009 Assembly (hg19): http://genome.ucsc.edu/cgi-bin/hgGateway.
20. Available from PubMed: http://www.ncbi.nlm.nih.gov/pubmed.
21. Available from MicrocosmTargets:http://www.ebi.ac.uk/enright-srv/ microcosm/htdocs/targets/v5/.
22. Available from miRanda: http://microrna.sanger.ac.uk/sequences/index. shtml.
23. Available from TargetScan http://www.targetscan.org/.
24. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007;7:819-22. (Pubitemid 350006254)
25. Pierson J, Hostager B, Fan R, Vibhakar R. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol 2008;90:1-7.
26. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, Khan SA. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008;27:2575-82. (Pubitemid 351550884)
27. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, et al. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 2011;71:2381-91.
28. Gao C, Zhang Z, Liu W, Xiao S, Gu W, Lu H. Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer 2010;116:41-9.
29. Song L, Huang Q, Chen K, Liu L, Lin C, Dai T, et al. miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-beta. Biochem Biophys Res Commun 2010;402:135-40.
30. Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Uchida Y, Kawahara K, et al. Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol Oncol 2010[Epub ahead of print].
31. Wu DW, Cheng YW, Wang J, Chen CY, Lee H. Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res 2010;70:10392-401.
32. Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 2010;6:e1000879.
33. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005;280:40406-16. (Pubitemid 41780527)
34. Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K, et al. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci 2006;97:1351-8. (Pubitemid 44614987)
35. Svoboda P. Off-targeting and other non-specific effects of RNAi experiments in mammalian cells. Curr Opin Mol Ther 2007;9:248-57. (Pubitemid 46944316)
36. Davidson MR, Larsen JE, Yang IA, Hayward NK, Clarke BE, Duhig EE, et al. MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS One 2010;5:e12560.
37. Nakamura E, Kozaki K, Tsuda H, Suzuki E, Pimkhaokham A, Yamamoto G, et al. Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. Cancer Sci 2008;99:1390-400. (Pubitemid 351761729)
38. Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER, et al. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res 2002;62:5874-80. (Pubitemid 35204748)
39. Dickinson RE, Dallol A, Bieche I, Krex D, Morton D, Maher ER, et al. Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers. Br J Cancer 2004;91:2071-8. (Pubitemid 40128774)
40. Narayan G, Goparaju C, Arias-Pulido H, Kaufmann AM, Schneider A, Durst M, et al. Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer 2006;5:16.
41. Li X, Shen Y, Ichikawa H, Antes T, Goldberg GS. Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration. Oncogene 2009;28:4272-83.
42. Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer 2010;9:57.
43. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009;15:148-59.